Ivermectin vs Fenbendazole vs Mebendazole for Cancer: What Does the Evidence Actually Show? (2026 Update)

November 13, 2026

A comprehensive comparison of three antiparasitic drugs, their proposed anticancer mechanisms, human clinical evidence, the emerging triple combination (IFM), safety concerns and the potential for future drug repurposing.

Evidence review updated: November 2026

Key message: Ivermectin, fenbendazole, and mebendazole have demonstrated biological activity in selected preclinical cancer models. However, none is an established cancer treatment, and all remain investigational. The triple combination of ivermectin, fenbendazole, and mebendazole (IFM) is likewise an investigational hypothesis, with no demonstrated clinical efficacy or validated evidence of synergistic activity.

Introduction: Three antiparasitic drugs attracting attention in oncology

Ivermectin, fenbendazole and mebendazole have attracted considerable attention in cancer research and online discussions about drug repurposing.

All three are antiparasitic medications, but they belong to different pharmacological categories and have substantially different regulatory statuses, pharmacokinetic properties and levels of human clinical evidence.

Their scientific interest comes from observations that some of their biological effects extend beyond their established antiparasitic functions.

Laboratory research has suggested that these compounds may influence several processes relevant to cancer biology, including:

Microtubule function and cell division.
Apoptosis and programmed cell death.
Cancer-related signalling pathways.
Cellular metabolism and mitochondrial function.
Angiogenesis and tumour blood-vessel formation.
Cellular stress responses and treatment resistance.

These findings have generated interest in whether existing medicines could eventually be repurposed for oncology.

However, an important distinction must be maintained:

Evidence that a compound affects cancer cells experimentally is not evidence that it treats cancer in humans.

A laboratory finding must pass several stages of investigation before it can become a clinically useful treatment. Researchers must establish achievable drug concentrations, tumour penetration, appropriate dosing, safety, interactions with existing treatments and, ultimately, improvements in meaningful patient outcomes.

This article examines the three compounds according to those standards rather than assuming that promising biochemical mechanisms translate into therapeutic effectiveness.

1. Executive comparison

Characteristic	Ivermectin	Fenbendazole	Mebendazole
Drug class	Macrocyclic lactone	Benzimidazole	Benzimidazole
Established human use	Yes, selected parasitic infections	No; veterinary medication	Yes, selected parasitic infections
Main oncology research	Cellular signalling, mitochondrial function and drug-resistance pathways	Microtubules, glucose metabolism and cellular stress	Microtubules, angiogenesis and tumour signalling
Preclinical research	Substantial	Experimental	Substantial
Human oncology research	Early clinical investigation	No established clinical efficacy	Phase I and Phase II studies
Approved cancer treatment	No	No	No
Established cancer survival benefit	None demonstrated	None demonstrated	None demonstrated

The three compounds should not be treated as interchangeable.

Mebendazole has the most developed human oncology research among them. Ivermectin has entered early clinical investigation in combination with immunotherapy. Fenbendazole remains substantially less developed from a human clinical and regulatory perspective.

None has established a role as a standard cancer treatment.

2. Ivermectin: Multiple proposed anticancer mechanisms

Background

Ivermectin is an antiparasitic medication used in humans for selected parasitic infections. It is also widely used in veterinary medicine.

Its anticancer research interest comes from laboratory observations involving several cellular pathways.

Proposed mechanisms

1. WNT/β-catenin signalling

Some cancer models suggest that ivermectin can interfere with WNT/β-catenin signalling, a pathway involved in cellular proliferation, differentiation and tumour development.

This pathway is relevant to several malignancies, including colorectal cancer. However, inhibiting a signalling pathway in a cancer cell line does not establish clinical effectiveness against a tumour carrying abnormalities in that pathway.

2. Apoptosis induction

Experimental studies have reported activation of apoptosis through mitochondrial dysfunction, changes in cellular signalling and activation of caspases.

The extent of these effects varies across experimental models.

3. Importin α/β nuclear transport

Ivermectin has been investigated as an inhibitor of importin-mediated nuclear transport.

This is scientifically interesting because nuclear transport helps regulate the movement of proteins involved in cell growth and survival.

It remains an experimental mechanism rather than an established anticancer action in patients.

4. PAK1 signalling

P21-activated kinase 1 (PAK1) is involved in cell survival, proliferation and migration.

Some experimental studies have suggested that ivermectin can interfere with PAK1-related signalling.

Whether this mechanism can be exploited safely and effectively in human tumours remains uncertain.

5. AKT/mTOR signalling

The AKT/mTOR pathway regulates cellular growth, metabolism and survival.

Ivermectin has demonstrated effects on this pathway in selected cancer models, including experimental ovarian cancer research.

6. Mitochondrial function

Some studies suggest that ivermectin can disrupt mitochondrial membrane potential and cellular energy production in cancer cells.

The challenge is determining whether an effective and tolerable exposure can be achieved in patients.

Other investigated mechanisms

Additional experimental research has explored effects on:

Autophagy.
Angiogenesis.
Cancer stem-cell-like populations.
Reactive oxygen species.
Cellular drug transporters.
Tumour-cell migration and proliferation.

These findings should be understood as a collection of experimental observations, not twelve independently validated clinical mechanisms.

Antiviral activity should also not be presented as proof that ivermectin suppresses virus-associated cancers in patients. These are separate research questions.

Human clinical evidence

The most relevant current oncology investigation is:

Clinical trial: NCT05318469

A Phase I/II study at Cedars-Sinai investigates ivermectin in combination with immune checkpoint inhibitors, including pembrolizumab and balstilimab, in patients with metastatic triple-negative breast cancer.

The study examines safety, tolerability, dosing and preliminary efficacy outcomes.

The ClinicalTrials.gov record was last updated on 5 August 2026 and listed the study as recruiting. No results were posted in the registry record at that update.

This is an important development because it represents formal clinical investigation of ivermectin in oncology.

Nevertheless, a registered clinical trial does not establish that the drug works. Its results must be evaluated when available.

Clinical trial: NCT05318469 — Ivermectin with immune checkpoint inhibitors in metastatic triple-negative breast cancer.

Limitations

Several questions remain unanswered:

Can anticancer concentrations be achieved safely in human tumours?
Are the laboratory effects reproducible in patients?
Does ivermectin improve the effectiveness of immunotherapy?
Could it interfere with other medicines or immune-related processes?
Does it improve progression-free survival or overall survival?

There is currently insufficient clinical evidence to recommend ivermectin for cancer treatment.

3. Fenbendazole: Microtubules, metabolism and oxidative stress

Background

Fenbendazole is a benzimidazole antiparasitic medication used in veterinary medicine.

Unlike ivermectin and mebendazole, it is not approved for human use.

Interest in fenbendazole as a potential cancer treatment largely developed from preclinical research and anecdotal accounts circulating online.

One frequently cited study was published in Scientific Reports in 2018:

Dogra N, Kumar A, Mukhopadhyay T.

Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways.

Scientific Reports. 2018;8:11926. DOI: 10.1038/s41598-018-30158-6.

The research investigated fenbendazole's effects on cancer cells and reported several biological changes.

These findings generated interest in further investigation, but they did not establish a treatment for human cancer.

Proposed mechanisms

1. Microtubule disruption

Microtubules are structural components of cells and are essential for chromosome separation during cell division.

Fenbendazole has demonstrated microtubule-disrupting activity in experimental models.

This is relevant because several established chemotherapy drugs also interfere with microtubule function.

However, sharing a biological target does not mean that fenbendazole has the same clinical properties or effectiveness as approved chemotherapy agents.

2. Glucose metabolism

Some experimental studies have reported changes in glucose uptake and glucose-metabolism pathways following fenbendazole exposure.

This has generated interest in its potential relationship with cancer metabolism.

However, cancer metabolism is heterogeneous. Not all cancers have the same metabolic requirements, and inhibiting glucose-related processes in experimental systems does not establish selective tumour starvation in patients.

3. p53 signalling

The p53 tumour suppressor pathway regulates DNA damage responses, cell-cycle arrest and apoptosis.

Some preclinical findings suggest that fenbendazole can influence p53-related processes.

This should not be interpreted as restoring normal p53 function in human cancers, particularly because TP53 abnormalities differ substantially between tumour types.

4. Oxidative stress

Fenbendazole has been investigated for its effects on reactive oxygen species and cellular redox balance.

In experimental systems, oxidative stress can contribute to cancer-cell injury.

However, this does not establish tumour-selective oxidative damage or clinical benefit.

5. Apoptosis and cell-cycle regulation

Experimental studies have reported cell-cycle arrest and apoptosis following fenbendazole exposure.

These mechanisms are potentially relevant to cancer research but require clinical validation.

Human clinical evidence

This is where fenbendazole has a major limitation.

There is no established body of prospective human oncology research demonstrating that fenbendazole improves tumour response, progression-free survival or overall survival.

There is also no validated human cancer dosage or established therapeutic window.

Individual stories of cancer regression or remission cannot establish that fenbendazole caused the outcome.

Cancer patients may receive surgery, radiotherapy, chemotherapy, immunotherapy or other interventions. Their disease can also follow unpredictable trajectories.

Without controlled comparisons and reliable clinical documentation, attributing an outcome to fenbendazole is scientifically unjustified.

Safety concerns

Fenbendazole should not be regarded as harmless simply because it is used in animals.

Published reports have documented fenbendazole-associated drug-induced liver injury in people who self-administered veterinary formulations.

A 2024 case report described severe liver injury following fenbendazole self-administration.

A further 2026 report described severe drug-induced liver injury following concurrent use of veterinary fenbendazole and ivermectin by a patient with prostate cancer.

These reports do not establish the frequency of harm, but they demonstrate that serious toxicity is possible.

Veterinary products also have formulations, concentrations and manufacturing standards that should not be assumed to be suitable for human administration.

Current assessment: Fenbendazole remains an experimental drug-repurposing hypothesis. It should not be recommended as a cancer treatment or as a substitute for established oncology care.

4. Mebendazole: The most developed clinical research of the three

Background

Mebendazole is a benzimidazole antiparasitic medication with established human use.

It has attracted particular interest in brain tumour research because of its effects on microtubules and several signalling pathways involved in tumour growth.

Unlike fenbendazole, mebendazole has progressed into human oncology studies.

That distinction is important, although it does not mean that its effectiveness as a cancer treatment has been established.

Proposed mechanisms

1. Microtubule disruption

Mebendazole interferes with tubulin polymerisation and microtubule formation.

This can disrupt cell division and produce mitotic arrest in experimental cancer models.

2. Angiogenesis inhibition

Preclinical studies have investigated effects on vascular endothelial growth factor receptor signalling and other processes involved in the development of new blood vessels.

3. Apoptosis

Mebendazole has demonstrated apoptosis-related effects in experimental models, including changes involving caspases and members of the BCL-2 protein family.

4. Hedgehog and other oncogenic signalling pathways

Research has examined the possibility that mebendazole influences Hedgehog signalling and other pathways involved in cancer growth.

5. Combination research

Mebendazole has been investigated alongside chemotherapy and radiotherapy in experimental models.

Some findings suggest that it may enhance the effects of other treatments under particular laboratory conditions.

This remains a research question, not proof of clinical synergy.

Why brain tumours have attracted particular interest

One of the important research questions concerns mebendazole's formulation and its ability to reach brain tissue.

Mebendazole exists in different crystalline forms, or polymorphs. Polymorph C has demonstrated improved brain penetration compared with other forms in certain preclinical models.

However, this should not be simplified into a claim that mebendazole reliably achieves therapeutic concentrations in human brain tumours.

Its poor aqueous solubility, variable absorption and transport by drug-efflux proteins remain important challenges.

Human clinical evidence

Mebendazole has progressed further than ivermectin and fenbendazole in clinical oncology investigation.

Three areas of research are particularly relevant.

Study 1: Newly diagnosed high-grade gliomas

A Phase I clinical study investigated mebendazole in combination with temozolomide in patients with newly diagnosed high-grade gliomas.

Twenty-four patients were enrolled.

The study reported a median overall survival of 21 months. However, it was a single-arm study without a control group receiving the same treatment without mebendazole. Therefore, the survival outcome cannot be attributed to mebendazole.

Four patients receiving the highest studied dose developed grade 3 elevations in liver enzymes, which improved following dose reduction or discontinuation.

Reference:

Mukhopadhyay T et al.

Mebendazole and temozolomide in patients with newly diagnosed high-grade gliomas: Results of a phase 1 clinical trial.

Neuro-Oncology Advances. 2020. DOI: 10.1093/noajnl/vdaa154.

Study 2: Recurrent glioblastoma – randomized Phase II study

A randomized Phase II study investigated mebendazole combined with either temozolomide or lomustine in patients with recurrent glioblastoma.

A total of 88 patients were randomized between the two treatment combinations.

The predefined nine-month overall survival benchmark was 55%.

The reported nine-month overall survival was:

Temozolomide plus mebendazole: 36.6%.
Lomustine plus mebendazole: 45.0%.

Neither treatment arm met the predefined benchmark.

Importantly, both arms contained mebendazole. The trial therefore did not establish whether adding mebendazole improved outcomes compared with temozolomide or lomustine alone.

Reference:

Patil VM et al.

Mebendazole plus lomustine or temozolomide in patients with recurrent glioblastoma: A randomised open-label phase II trial.

EClinicalMedicine. 2022. DOI: 10.1016/j.eclinm.2022.101449.

Study 3: Recurrent or progressive paediatric brain tumours

A Phase I study published in 2025 investigated mebendazole in children with recurrent or progressive brain tumours.

The study added to the human safety and feasibility literature, but it did not establish mebendazole as an effective treatment for these tumours.

What does the latest systematic review conclude?

A systematic review published in May 2026 examined mebendazole research in brain tumours.

The review found substantial experimental interest but highlighted important translational and pharmacokinetic challenges. Existing human evidence does not establish meaningful efficacy in brain tumour patients.

Reference:

Blum CB et al.

From anthelmintic to neuro-oncology: A systematic review of mebendazole repurposing for brain tumour therapy.

British Journal of Clinical Pharmacology. 2026. DOI: 10.1002/bcp.70565.

Current assessment: Mebendazole is a legitimate subject for further clinical investigation, particularly in neuro-oncology. However, it is not an established brain cancer treatment.

Its long history of human use against parasites should also not be taken as proof that substantially higher oncology-study exposures are equally safe.

5. The triple combination: Ivermectin, Fenbendazole and Mebendazole (IFM)

5.1 Why is the triple combination attracting attention?

Beyond investigating ivermectin, fenbendazole and mebendazole individually, some researchers and integrative oncology practitioners have become interested in combining the three medications.

The proposed combination is commonly referred to as IFM:

I – Ivermectin
F – Fenbendazole
M – Mebendazole

The scientific rationale is based on the possibility that these agents may affect different, partially overlapping biological processes involved in cancer development.

Proposed target	Investigational drug association	Research rationale
Microtubule function	Fenbendazole and mebendazole	Interference with cell division
Oncogenic signalling	Ivermectin	Effects on selected pathways including WNT/β-catenin and AKT/mTOR
Cellular metabolism	All three, in different experimental models	Potential effects on cellular energy pathways
Apoptosis	All three in experimental models	Changes in pathways regulating programmed cell death
Angiogenesis	Particularly mebendazole	Potential interference with tumour blood-vessel formation
Cellular stress	Fenbendazole and ivermectin, among others	Effects involving oxidative stress and mitochondrial function

The theoretical attraction is that different cellular targets might be affected simultaneously.

However, overlapping biological effects do not automatically translate into synergistic anticancer activity.

A combination is synergistic only when its combined effects are demonstrably greater than those expected from the individual compounds under appropriately controlled experimental conditions.

To date, clinical synergy of the ivermectin–fenbendazole–mebendazole combination has not been established.

5.2 Preclinical evidence: What do we actually know?

The three drugs have independently demonstrated biological effects in selected cancer-cell and animal models.

Some dual-agent combinations have also been investigated.

However, the evidence needs to be separated into three categories:

Individual-drug research

There is an established body of laboratory literature examining the biological effects of ivermectin, fenbendazole and mebendazole separately.

Dual-agent research

Some studies have explored combinations of these compounds and other anticancer agents. Results from individual experiments cannot be generalized across cancer types or drug combinations.

Triple-agent research

The OneDayMD IFM review reported that triple-agent synergy had not been systematically quantified in cell-culture studies and that no triple-agent animal studies had been identified in its review.

This is a major research gap.

We therefore cannot conclude that IFM is more effective than ivermectin, fenbendazole or mebendazole individually.

Nor can we assume that combining three experimental agents produces a stronger, safer or more selective anticancer effect.

5.3 Human observations: OneDayMD's compilation of 31 publicly reported cases

OneDayMD published a compilation titled:

Triple Combination of Ivermectin, Mebendazole and Fenbendazole (IFM) for Cancer: 31 Case Reports (October 2026).

The article collected publicly reported patient narratives, predominantly sourced from social-media posts, describing the use of ivermectin, fenbendazole and mebendazole in people with cancer.

The reported malignancies included:

Lung cancer, including non-small cell lung cancer.
Breast cancer, including triple-negative breast cancer.
Prostate cancer.
Pancreatic cancer.
Endometrial and other uterine cancers.
Colorectal and rectal cancers.
Ovarian cancer.
Cervical cancer.
Neuroendocrine cancers.
Brain tumours, including gliomas.
Hodgkin lymphoma.
Bladder cancer.

Reported observations included tumour-size reductions, changes in PET/CT findings, declines in tumour-associated biomarkers and improvements in symptoms.

These observations are potentially relevant to hypothesis generation, but their evidential limitations are substantial.

An important distinction about the reported cases:

The compilation should not be interpreted as 31 independently documented cases of simultaneous triple-drug treatment.

Its individual narratives include:

Patients receiving all three medications.
Patients initially receiving two medications before the third was added.
Sequential switching between fenbendazole and mebendazole.
Cases involving other agents, including niclosamide.
Patients receiving conventional chemotherapy, radiotherapy, immunotherapy or targeted therapy concurrently.
Patients who discontinued conventional cancer treatment.

The abstract reports 29 triple-combination cases and one quadruple-combination case, which totals 30. However, the main article presents 31 numbered case narratives.

Additionally, the case list includes examples that do not represent simultaneous use of all three drugs throughout treatment.

These discrepancies should be reconciled before the compilation is described as a defined series of 31 IFM-treated patients.

5.4 What do these reports contribute?

Their principal contribution is documenting observations that may generate research questions.

For example:

Could some patients experience tumour responses while taking these drugs?
Might particular biological or molecular characteristics influence responses?
Could the combination interact with conventional cancer treatments?
Are there identifiable patterns of toxicity?
Can any observed response be reproduced in properly controlled research?

These are legitimate questions for investigation.

They are not established answers.

5.5 Why the reported responses cannot establish efficacy

Several methodological limitations prevent the compilation from demonstrating that IFM causes cancer regression.

1. Concurrent conventional treatments

Some patients received chemotherapy, immunotherapy, radiotherapy or targeted therapy alongside the antiparasitic medications.

For example, some narratives describe concurrent use of pembrolizumab, chemotherapy or other established cancer treatments.

When multiple interventions are administered together, it is impossible to determine which intervention produced a particular response.

Improvement may have resulted from standard treatment, the combination, another intervention or several factors.

2. Lack of independent clinical verification

Social-media testimonials are not equivalent to independently assessed medical records.

Establishing a response requires verification of the original diagnosis, pathology, staging, treatment history, baseline imaging, follow-up imaging and subsequent clinical outcomes.

These data are not consistently available in the published compilation.

3. Different definitions of response

The narratives include several different types of outcomes:

Tumour diameter or volume changes.
PET scan changes.
PSA, CEA and other tumour-marker declines.
Circulating tumour DNA changes.
Symptomatic improvement.
Patient-reported remission.

These outcomes cannot be treated as interchangeable.

A decline in a tumour marker does not necessarily establish radiological response, and radiological response does not automatically demonstrate longer survival.

One reported lung-tumour size reduction was calculated using Grok rather than an independently validated radiological measurement. Such an estimate should not be treated as a clinical response endpoint.

4. Selection and publication bias

Patients with favourable experiences are more likely to share their stories publicly.

Patients who experience no improvement, disease progression, treatment discontinuation or toxicity may be less likely to be represented.

Without a defined population of all people using IFM, including those with unsuccessful outcomes, there is no reliable denominator from which to calculate response rates.

5. No controlled comparison

There is no randomized comparison between:

IFM alone.
Ivermectin alone.
Fenbendazole alone.
Mebendazole alone.
Standard cancer treatment.
Standard cancer treatment combined with IFM.

Consequently, these reports cannot establish whether IFM improves outcomes compared with established treatment.

6. Incomplete safety information

The compilation does not provide systematic, independently collected adverse-event data for all patients.

The absence of reported toxicity in a testimonial does not mean that no toxicity occurred.

Long-term safety, liver injury, neurological effects and interactions with conventional cancer medications remain important unresolved issues.

5.6 Is there evidence of synergy?

The theoretical combination is interesting, but evidence of synergy is currently insufficient.

To establish synergy, researchers would need to investigate:

Whether the three compounds interact favourably at relevant concentrations.
Whether the combination produces stronger effects than individual drugs and dual combinations.
Whether these effects are reproducible across different cancer models.
Whether achievable human exposure is sufficient to reproduce the experimental effects.
Whether any additional antitumour effect comes at an unacceptable toxicity cost.

A combination that kills more cells in a laboratory dish is not necessarily a clinically useful combination.

Three drugs may also interact in ways that reduce effectiveness or increase toxicity.

The claim that ivermectin increases tumour concentrations of benzimidazoles through P-glycoprotein inhibition should also be regarded as a hypothesis, not an established clinical result.

Therefore, the IFM combination should be regarded as an experimental research hypothesis rather than a validated multi-target cancer treatment.

5.7 Safety: The risk–benefit question remains unanswered

The suggestion that the combination has a high potential benefit and relatively low risk is not supported by the available case compilation.

The established safety of ivermectin and mebendazole at approved antiparasitic doses cannot be extrapolated to prolonged, high-exposure oncology regimens.

Fenbendazole presents an additional concern because it is a veterinary medication that has not been approved for human use.

Published cases of fenbendazole-associated liver injury demonstrate that serious adverse effects are possible.

The following questions remain unanswered:

What is the safety profile of prolonged concurrent administration?
Does one medication alter the metabolism or exposure of another?
Could the combination increase liver toxicity?
Could it interfere with chemotherapy or immunotherapy?
What happens when patients take additional supplements and repurposed medicines?
Is there an acceptable therapeutic window?

Liver-function monitoring alone cannot establish that an experimental regimen is safe.

The American Society of Clinical Oncology (ASCO), in its June 2026 Clinical Notice, cautioned against using ivermectin and fenbendazole to treat cancer or as adjuncts to established cancer therapy outside a properly designed clinical trial.

Reference: ASCO Clinical Notice, 17 June 2026.

5.8 What research is needed next?

The IFM hypothesis deserves to be tested scientifically rather than evaluated through increasingly large collections of testimonials.

A sensible translational research pathway would include:

Stage 1: Laboratory evaluation

Compare individual drugs, dual combinations and the triple combination across appropriately selected cancer models.

Use formal combination-index and dose-response methods to distinguish additive effects from genuine synergy.

Stage 2: Pharmacokinetic and pharmacodynamic research

Determine whether experimental concentrations are achievable in humans and whether the drugs influence each other's absorption, metabolism and distribution.

Stage 3: Animal studies

Investigate whether the triple combination produces reproducible antitumour effects and whether the combination has an acceptable safety profile.

Stage 4: Early-phase clinical investigation

Only after adequate preclinical and regulatory review should a properly designed human study establish safety, tolerability and appropriate exposure.

Stage 5: Controlled clinical trials

Any claim of improved cancer outcomes would ultimately require comparison against appropriate standard treatment, using objective response, progression-free survival, overall survival and quality-of-life measures.

The three-drug combination has not yet established this evidence pathway.

Interim assessment of IFM

The IFM combination is scientifically interesting because it brings together three compounds with different experimental pharmacological properties.

The publicly reported patient narratives are worth documenting as anecdotal observations, but they cannot establish effectiveness or safety.

The absence of controlled evidence is particularly important because several cases involve simultaneous conventional treatments, making attribution difficult.

Our position: IFM is an investigational drug-repurposing hypothesis, not an established cancer treatment protocol.

Further research may clarify whether any component or combination has clinical value. Until then, the combination should not replace or be added to standard cancer treatment outside a properly designed clinical trial.

6. Important 2026 research-integrity update

A prospective observational study titled Real-world Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort was published in Anticancer Research in June 2026.

It initially reported favourable outcomes among patients using ivermectin and mebendazole.

However, the journal subsequently issued an Expression of Concern in June, an update in September and formally retracted the article in October 2026.

The retraction followed post-publication review, independent expert assessment and consideration of the authors' responses. The editor identified methodological and analytical problems.

Consequently, the reported outcomes should not be cited as evidence that ivermectin and mebendazole improve cancer survival or produce tumour regression.

This is an important example of why publication in a peer-reviewed journal is not the end of the evidence-assessment process.

Researchers and readers must also monitor corrections, expressions of concern and retractions.

References:

Important distinction: This retracted study investigated ivermectin and mebendazole. It was not a controlled clinical trial of the IFM triple combination.

7. Safety, interactions and the importance of oncologist supervision

The fact that a drug is already used for a non-cancer condition does not mean that it can be safely repurposed for cancer at higher doses or for prolonged periods.

The three compounds have different safety considerations.

Ivermectin

Ivermectin has established human use for selected parasitic diseases. However, excessive exposure, inappropriate formulations and interactions with other medications can produce toxicity, including neurological effects.

Its safety in approved applications does not automatically establish safety in experimental oncology regimens.

Fenbendazole

Fenbendazole is not approved for human use.

Human pharmacokinetic and long-term safety information is limited. Published case reports of liver injury provide a particular reason for caution.

Veterinary formulations should not be used as substitutes for human medicines.

Mebendazole

Mebendazole has an established human safety record at approved antiparasitic doses.

However, oncology investigations have used different and substantially higher exposures. Elevated liver enzymes and other adverse events have been reported in these studies.

Safety must therefore be assessed according to the actual dose, duration, formulation and combination of medicines being studied.

Patients should disclose all supplements, antiparasitic medications and non-prescribed treatments to their oncology team.

They should not stop, delay or replace prescribed cancer treatment on the basis of laboratory findings, online testimonials or unverified treatment protocols.

8. What should we conclude about drug repurposing?

Drug repurposing is an important area of oncology research.

An existing medicine may have biological effects that have not yet been fully explored. Investigating these effects can sometimes identify new therapeutic opportunities and potentially shorten parts of the drug-development process.

However, repurposing requires the same scientific discipline as developing a new cancer medicine.

A plausible mechanism must be followed by:

Reproducible laboratory findings.
Pharmacokinetic and pharmacodynamic studies.
Appropriate dose-finding and safety studies.
Early-phase clinical investigation.
Properly controlled trials evaluating clinical benefit.
Independent confirmation of efficacy and safety.

The three medications illustrate different stages of this process.

Ivermectin: Interesting experimental mechanisms and an early clinical investigation in metastatic triple-negative breast cancer, but no established anticancer benefit.

Fenbendazole: Experimental anticancer findings, predominantly preclinical, without established human oncology efficacy or an approved human-use formulation.

Mebendazole: The most developed human oncology research among the three, particularly in brain tumours, but clinical evidence remains insufficient to establish meaningful treatment benefit.

IFM triple combination: A further research hypothesis supported by public anecdotal narratives, but without demonstrated triple-agent synergy, controlled clinical efficacy or a validated safety profile.

9. Final perspective: Promising hypothesis versus proven treatment

The scientific interest in ivermectin, fenbendazole and mebendazole should not be dismissed simply because their anticancer applications remain unproven.

Equally, promising laboratory observations should not be promoted as established treatments.

The important question is not how many pathways a compound affects, how many cancer cell lines it can inhibit, or how many anecdotes circulate online.

It is whether the drug can be administered safely, reach the tumour at an effective concentration, produce a reproducible response and ultimately improve the patient's quality of life or survival.

That is the difference between a promising biochemical hypothesis and a clinically validated cancer treatment.

Our guiding principle: Investigate promising possibilities, but do not confuse biological plausibility, anecdotal observations and clinical proof.

References and further reading

Ivermectin

Juarez M, Schcolnik-Cabrera A, Dueñas-Gonzalez A. The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug. American Journal of Cancer Research. 2018;8(2):317–331. PubMed.
ClinicalTrials.gov. Ivermectin in combination with balstilimab or pembrolizumab in metastatic triple-negative breast cancer. NCT05318469. Clinical trial record.

Fenbendazole

Dogra N, Kumar A, Mukhopadhyay T. Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways. Scientific Reports. 2018;8:11926. DOI.
Thakurdesai A et al. Severe drug-induced liver injury due to self-administration of the veterinary anthelmintic medication, fenbendazole. ACG Case Reports Journal. 2024. DOI.
Powderly GE et al. Drug-induced liver injury following co-ingestion of veterinary fenbendazole and ivermectin for prostate cancer: A case report. Cureus. 2026. DOI.

Mebendazole

Mukhopadhyay T et al. Mebendazole and temozolomide in patients with newly diagnosed high-grade gliomas: Results of a phase 1 clinical trial. Neuro-Oncology Advances. 2020. DOI.
Patil VM et al. Mebendazole plus lomustine or temozolomide in patients with recurrent glioblastoma: A randomised open-label phase II trial. EClinicalMedicine. 2022. DOI.
Blum CB et al. From anthelmintic to neuro-oncology: A systematic review of mebendazole repurposing for brain tumour therapy. British Journal of Clinical Pharmacology. 2026. DOI.

Others

OneDayMD. Triple Combination of Ivermectin, Mebendazole and Fenbendazole (IFM) for Cancer: 31 Case Reports. Original case compilation.
American Society of Clinical Oncology. Oncologists urged to take proactive approach when discussing ivermectin and fenbendazole. 17 June 2026. ASCO Clinical Notice.
Hulscher N et al. Real-world Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort. RETRACTED. Anticancer Research. 2026. PubMed retraction record.
Page MJ et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. DOI.
Repurposed Oncology. Comparative analysis: Ivermectin vs Fenbendazole vs Mebendazole. 2026.

Editorial and medical disclaimer

This article is an independent scientific evidence review and is intended for educational purposes. It does not recommend ivermectin, fenbendazole or mebendazole as cancer treatments.

None of these drugs has established efficacy as a cancer treatment. The discussion of experimental mechanisms does not constitute a treatment recommendation.

Clinical decisions should be made with qualified oncology professionals. Established cancer treatments should not be discontinued or replaced on the basis of unproven drug-repurposing claims.

Last evidence review: 13 November 2026.